[Economic evaluation of the introduction of 4CMenB (Bexsero ®) in the national vaccine schedule in Spain].

CONCLUSIONS: Given the current incidence of invasive meningococcal disease in Spain and the information available from 4CMenB, our model shows that routine vaccination is not cost-effective at the current price. Only with a vaccine price of 1.45 € for the 3+1 schedule or 3.37 € for the 2+1 schedule could it be recommended based on efficiency criteria. PMID: 31776044 [PubMed - as supplied by publisher]
Source: Gaceta Sanitaria - Category: International Medicine & Public Health Tags: Gac Sanit Source Type: research